F8 and pulmonary embolism: Four of the 24 patients (17%) in our review died: one because of suspected intracranial hemorrhage (without autopsy confirmation, so a thrombotic event was not excluded; treated with aPCC and rFVIIa) [22]; one because of pulmonary embolism possibly attributed to aPCC treatment (dose unspecified) [15]; and one because of cardiac arrest following a stroke (treated with FVIII, rFVIIa, and rpFVIII; Table 1) [20].